Literature DB >> 6189287

Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants.

P N Graves, J L Schulman, J F Young, P Palese.   

Abstract

Acid treatment of influenza A and B virus preparations followed by addition of dithiothreitol (DTT) and centrifugation through a sucrose cushion removes the HA1 subunit of hemagglutinin from virus. Rabbit sera made against these subviral particles and untreated virus were tested in a radioimmune precipitation assay using [35S]cysteine-labeled virus. Conditions of the assay permitted discrimination of discrete HA1- and HA2-specific antibody populations. It was found that (a) sera raised to intact influenza A virus preparations contained both HA1- and HA-2 specific antibodies, (b) sera made to subviral particles of influenza A virus contained HA2-specific antibody but had little or no detectable HA1-specific antibody. (c) the HA2-specific antibodies were partially cross-reactive with the HA2 of an influenza A virus of a different subtype, and (d) sera raised against two strains of untreated influenza B viruses contained antibodies which were cross-reactive with the HA2 as well as the NP of influenza A viruses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189287     DOI: 10.1016/0042-6822(83)90465-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  67 in total

1.  Protonation and stability of the globular domain of influenza virus hemagglutinin.

Authors:  Qiang Huang; Robert Opitz; Ernst-Walter Knapp; Andreas Herrmann
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

2.  Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection.

Authors:  Zuzana Staneková; Vojtech Mucha; Tatiana Sládková; Hana Blaškovičová; František Kostolanský; Eva Varečková
Journal:  Influenza Other Respir Viruses       Date:  2012-01-12       Impact factor: 4.380

Review 3.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

4.  An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses.

Authors:  Hsueh-Ling Janice Oh; Sara Akerström; Shuo Shen; Sándor Bereczky; Helen Karlberg; Jonas Klingström; Sunil K Lal; Ali Mirazimi; Yee-Joo Tan
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

5.  Quality control in the secretory pathway: the role of calreticulin, calnexin and BiP in the retention of glycoproteins with C-terminal truncations.

Authors:  J X Zhang; I Braakman; K E Matlack; A Helenius
Journal:  Mol Biol Cell       Date:  1997-10       Impact factor: 4.138

6.  Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin.

Authors:  G W Kemble; D L Bodian; J Rosé; I A Wilson; J M White
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice.

Authors:  W Gerhard; A M Haberman; P A Scherle; A H Taylor; G Palladino; A J Caton
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Conservation of epitopes recognized by monoclonal antibodies against the separated subunits of influenza hemagglutinin among type A viruses of the same and different subtypes.

Authors:  A Sanchez-Fauquier; M Guillen; J Martin; A P Kendal; J A Melero
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

Review 9.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

10.  Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin.

Authors:  P C Roberts; W Garten; H D Klenk
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.